Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 5 |
| List of Tables | 8 | 1 |
| List of Figures | 9 | 1 |
| Introduction | 10 | 1 |
| Therapeutic Landscape | 11 | 15 |
| Heart Failure | 11 | 1 |
| Symptoms | 11 | 1 |
| Etiology | 12 | 1 |
| Pathophysiology | 12 | 1 |
| Co-morbidities and Complications | 12 | 1 |
| Diagnosis | 13 | 1 |
| Classification | 14 | 1 |
| Prognosis and Disease Staging | 14 | 1 |
| Treatment Options | 15 | 1 |
| Angiotensin-Converting Enzyme Inhibitors | 15 | 1 |
| Angiotensin II Receptor Blockers | 15 | 1 |
| Beta Blockers | 15 | 1 |
| Digoxin | 16 | 1 |
| Diuretics | 16 | 1 |
| Aldosterone Antagonists | 16 | 1 |
| Hydralazine and Nitrates | 16 | 1 |
| Treatment Algorithms and Prescribing Habits | 16 | 2 |
| Myocardial Infarction | 18 | 1 |
| Symptoms | 18 | 1 |
| Etiology | 18 | 1 |
| Pathophysiology | 18 | 1 |
| Co-morbidities and Complications | 19 | 1 |
| Diagnosis | 19 | 1 |
| Classification | 20 | 1 |
| Treatment Options | 21 | 1 |
| Acute Coronary Syndrome | 22 | 1 |
| Symptoms | 22 | 1 |
| Etiology | 22 | 1 |
| Pathophysiology | 23 | 1 |
| Diagnosis | 23 | 1 |
| Treatment Options | 24 | 2 |
| Marketed Products | 26 | 12 |
| Heart Failure | 26 | 1 |
| Myocardial Infarction | 26 | 1 |
| Acute Coronary Syndrome | 26 | 1 |
| Key Marketed Products | 26 | 1 |
| Arixtra | 26 | 2 |
| Brilinta | 28 | 1 |
| Crestor | 29 | 1 |
| Diovan and Diovan HCT/Co-Diovan | 30 | 1 |
| Atacand | 30 | 1 |
| Lipitor | 31 | 1 |
| Clopidogrel bisulfate | 32 | 1 |
| Angiomax | 32 | 1 |
| Lovenox | 33 | 1 |
| Norvasc | 34 | 1 |
| Coreg | 34 | 2 |
| Ivabradine | 36 | 1 |
| Toprol-XL | 36 | 2 |
| Pipeline Analysis | 38 | 13 |
| Heart Failure Pipeline | 38 | 1 |
| Overall Pipeline | 38 | 1 |
| Pipeline Analysis by Molecule Type | 39 | 1 |
| Pipeline Analysis by Mechanism of Action | 40 | 1 |
| Myocardial Infarction Pipeline | 41 | 1 |
| Overall Pipeline | 41 | 1 |
| Pipeline Analysis by Molecule Type | 42 | 1 |
| Pipeline Analysis by Mechanism of Action | 43 | 1 |
| Acute Coronary Syndrome Pipeline | 44 | 1 |
| Overall Pipeline | 44 | 1 |
| Pipeline Analysis by Molecule Type | 45 | 1 |
| Pipeline Analysis by Mechanism of Action | 46 | 1 |
| Promising Drug Candidates in the Pipeline | 47 | 1 |
| LCZ-696 | 47 | 1 |
| Overview | 47 | 1 |
| Efficacy | 47 | 1 |
| Safety | 47 | 1 |
| Darapladib (SB-480848) | 48 | 1 |
| Overview | 48 | 1 |
| Efficacy | 48 | 1 |
| Safety | 48 | 1 |
| Neucardin | 49 | 1 |
| Overview | 49 | 1 |
| Efficacy | 49 | 1 |
| Safety | 49 | 1 |
| Cangrelor | 50 | 1 |
| Overview | 50 | 1 |
| Efficacy | 50 | 1 |
| Safety | 50 | 1 |
| Serelaxin (Novartis AG) | 50 | 1 |
| Market Forecast to 2019 | 51 | 12 |
| Asia-Pacific Market | 51 | 1 |
| Treatment Usage Patterns | 51 | 1 |
| Annual Cost of Therapy | 51 | 1 |
| Market Size | 51 | 2 |
| Australia | 53 | 1 |
| Treatment Usage Patterns | 53 | 1 |
| Annual Cost of Therapy | 53 | 1 |
| Market Size | 53 | 2 |
| China | 55 | 1 |
| Treatment Usage Patterns | 55 | 1 |
| Annual Cost of Therapy | 55 | 1 |
| Market Size | 55 | 2 |
| Japan | 57 | 1 |
| Treatment Usage Patterns | 57 | 1 |
| Annual Cost of Therapy | 57 | 1 |
| Market Size | 57 | 2 |
| India | 59 | 1 |
| Treatment Usage Patterns | 59 | 1 |
| Annual Cost of Therapy | 59 | 1 |
| Market Size | 59 | 2 |
| Drivers and Barriers for the Global Cardiovascular Diseases Market | 61 | 1 |
| Drivers | 61 | 1 |
| Approval of Generic Drugs is Key Factor in Tapping Asia-Pacific Region | 61 | 1 |
| Large Patient Pool | 61 | 1 |
| Healthcare Infrastructure Improvement | 61 | 1 |
| Japan s Public Healthcare Expenditure | 61 | 1 |
| Barriers | 62 | 1 |
| Lengthy Product Registration Processes | 62 | 1 |
| Lack of Reimbursement and Public Funding in Developing Countries | 62 | 1 |
| Deals and Strategic Consolidations | 63 | 9 |
| Deals Analysis | 63 | 2 |
| Major Co-Development Deals | 65 | 1 |
| Genzyme Enters into Agreement with Osiris Therapeutics | 66 | 1 |
| Les Laboratoires Servier Enters into Co-development Agreement with miRagen Therapeutics | 66 | 1 |
| Cytokinetics Signs Strategic Agreement with Amgen | 66 | 1 |
| Biogen Idec Inc. Enters into Agreement with Cardiokine Inc. | 66 | 1 |
| Bristol-Myers Squibb Enters into Co-Development Agreement with Ambrx Inc. | 67 | 1 |
| Angioblast Systems Inc. Enters into Co-Development Agreement with Abbott India Limited | 67 | 1 |
| Major Licensing Deals | 68 | 1 |
| Cephalon Inc. Enters into Licensing Agreement with Mesoblast Limited for Regenerative Medicine | 69 | 1 |
| The Medicines Company Enters into Licensing Agreement with Pfizer Inc. | 69 | 1 |
| BioLineRx, Ltd. Enters into Licensing Agreement With Ikaria Holdings, Inc. | 69 | 1 |
| KAI Pharmaceuticals, Inc. Enters into Licensing Agreement with Bristol-Myers Squibb | 69 | 1 |
| Theravance, Inc. Enters into Licensing Agreement with Merck &Co., Inc. for Cardiovascular Therapeutic Candidates | 70 | 1 |
| Novartis AG Enters into License Agreement with Portola Pharmaceuticals, Inc. | 71 | 1 |
| Salix Pharmaceuticals, Ltd. Enters into License Agreement with Merck &Co, Inc. | 71 | 1 |
| Amgen Enters into Licensing Agreement with Cytokinetics | 71 | 1 |
| Appendix | 72 | 22 |
| All Pipeline Drugs by Phase | 72 | 9 |
| Preclinical | 72 | 4 |
| Pre-registration | 76 | 1 |
| Phase I | 76 | 2 |
| Phase II | 78 | 2 |
| Phase III | 80 | 1 |
| Market Forecasts to 2019 | 81 | 5 |
| Global | 81 | 1 |
| Heart Failure | 81 | 1 |
| Myocardial Infarction | 81 | 1 |
| Acute Coronary Syndrome | 81 | 1 |
| Australia | 82 | 1 |
| Heart Failure | 82 | 1 |
| Myocardial Infarction | 82 | 1 |
| Acute Coronary Syndrome | 82 | 1 |
| China | 83 | 1 |
| Heart Failure | 83 | 1 |
| Myocardial Infarction | 83 | 1 |
| Acute Coronary Syndrome | 83 | 1 |
| Japan | 84 | 1 |
| Heart Failure | 84 | 1 |
| Myocardial Infarction | 84 | 1 |
| Acute Coronary Syndrome | 84 | 1 |
| India | 85 | 1 |
| Heart Failure | 85 | 1 |
| Myocardial Infarction | 85 | 1 |
| Acute Coronary Syndrome | 85 | 1 |
| Market Definitions | 86 | 1 |
| Abbreviations | 86 | 2 |
| Sources | 88 | 1 |
| Research Methodology | 89 | 5 |
| Coverage | 89 | 1 |
| Secondary Research | 89 | 1 |
| Primary Research | 90 | 1 |
| Therapeutic Landscape | 90 | 1 |
| Epidemiology-Based Forecasting | 91 | 1 |
| Market Size by Geography | 92 | 1 |
| Geographical Landscape | 93 | 1 |
| Pipeline Analysis | 93 | 1 |
| Expert Panel Validation | 93 | 1 |
| Contact Us | 93 | 1 |
| Disclaimer | 93 | 1 |
